Logo image of RCAT

RED CAT HOLDINGS INC (RCAT) Stock Fundamental Analysis

NASDAQ:RCAT - US75644T1007 - Common Stock

9.82 USD
+0.08 (+0.82%)
Last: 8/22/2025, 8:00:02 PM
9.89 USD
+0.07 (+0.71%)
Pre-Market: 8/25/2025, 6:46:51 AM
Fundamental Rating

2

RCAT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 124 industry peers in the Electronic Equipment, Instruments & Components industry. RCAT may be in some trouble as it scores bad on both profitability and health. RCAT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

RCAT had negative earnings in the past year.
In the past year RCAT has reported a negative cash flow from operations.
RCAT had negative earnings in each of the past 5 years.
RCAT had a negative operating cash flow in each of the past 5 years.
RCAT Yearly Net Income VS EBIT VS OCF VS FCFRCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

RCAT has a worse Return On Assets (-132.42%) than 92.74% of its industry peers.
With a Return On Equity value of -250.32%, RCAT is not doing good in the industry: 90.32% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -132.42%
ROE -250.32%
ROIC N/A
ROA(3y)-36.1%
ROA(5y)-55.7%
ROE(3y)-39.94%
ROE(5y)-95.13%
ROIC(3y)N/A
ROIC(5y)N/A
RCAT Yearly ROA, ROE, ROICRCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RCAT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCAT Yearly Profit, Operating, Gross MarginsRCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 0 0 0 0 0 0 0 0 0 0

3

2. Health

2.1 Basic Checks

RCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RCAT has more shares outstanding
Compared to 5 years ago, RCAT has more shares outstanding
Compared to 1 year ago, RCAT has an improved debt to assets ratio.
RCAT Yearly Shares OutstandingRCAT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RCAT Yearly Total Debt VS Total AssetsRCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

RCAT has an Altman-Z score of 19.18. This indicates that RCAT is financially healthy and has little risk of bankruptcy at the moment.
RCAT's Altman-Z score of 19.18 is amongst the best of the industry. RCAT outperforms 95.97% of its industry peers.
A Debt/Equity ratio of 0.44 indicates that RCAT is not too dependend on debt financing.
RCAT's Debt to Equity ratio of 0.44 is on the low side compared to the rest of the industry. RCAT is outperformed by 63.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z 19.18
ROIC/WACCN/A
WACC9.52%
RCAT Yearly LT Debt VS Equity VS FCFRCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.43 indicates that RCAT should not have too much problems paying its short term obligations.
The Current ratio of RCAT (1.43) is worse than 77.42% of its industry peers.
A Quick Ratio of 0.57 indicates that RCAT may have some problems paying its short term obligations.
The Quick ratio of RCAT (0.57) is worse than 93.55% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 0.57
RCAT Yearly Current Assets VS Current LiabilitesRCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

6

3. Growth

3.1 Past

The earnings per share for RCAT have decreased strongly by -17.31% in the last year.
Looking at the last year, RCAT shows a very negative growth in Revenue. The Revenue has decreased by -64.52% in the last year.
RCAT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 176.68% yearly.
EPS 1Y (TTM)-17.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)-64.52%
Revenue growth 3Y52.8%
Revenue growth 5Y176.68%
Sales Q2Q%-18.11%

3.2 Future

Based on estimates for the next years, RCAT will show a very strong growth in Earnings Per Share. The EPS will grow by 39.49% on average per year.
The Revenue is expected to grow by 123.37% on average over the next years. This is a very strong growth
EPS Next Y-7.95%
EPS Next 2Y49.03%
EPS Next 3Y39.49%
EPS Next 5YN/A
Revenue Next Year341.59%
Revenue Next 2Y188.86%
Revenue Next 3Y123.37%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RCAT Yearly Revenue VS EstimatesRCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M
RCAT Yearly EPS VS EstimatesRCAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4

1

4. Valuation

4.1 Price/Earnings Ratio

RCAT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
RCAT is valuated quite expensively with a Price/Forward Earnings ratio of 111.08.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RCAT is on the same level as its industry peers.
RCAT's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.81.
Industry RankSector Rank
PE N/A
Fwd PE 111.08
RCAT Price Earnings VS Forward Price EarningsRCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCAT Per share dataRCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

RCAT's earnings are expected to grow with 39.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.03%
EPS Next 3Y39.49%

0

5. Dividend

5.1 Amount

RCAT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

RED CAT HOLDINGS INC

NASDAQ:RCAT (8/22/2025, 8:00:02 PM)

Premarket: 9.89 +0.07 (+0.71%)

9.82

+0.08 (+0.82%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)09-22 2025-09-22
Inst Owners18.24%
Inst Owner Change58.85%
Ins Owners14.17%
Ins Owner Change-0.11%
Market Cap979.64M
Analysts84.44
Price Target14.62 (48.88%)
Short Float %19.81%
Short Ratio1.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-89.99%
Min EPS beat(2)-152.1%
Max EPS beat(2)-27.88%
EPS beat(4)0
Avg EPS beat(4)-100.39%
Min EPS beat(4)-152.1%
Max EPS beat(4)-27.88%
EPS beat(8)1
Avg EPS beat(8)-86.46%
EPS beat(12)2
Avg EPS beat(12)-132.75%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-46.29%
Min Revenue beat(2)-59.15%
Max Revenue beat(2)-33.43%
Revenue beat(4)0
Avg Revenue beat(4)-25.15%
Min Revenue beat(4)-59.15%
Max Revenue beat(4)-1.15%
Revenue beat(8)2
Avg Revenue beat(8)-16.41%
Revenue beat(12)3
Avg Revenue beat(12)-25.46%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.5%
PT rev (3m)2.38%
EPS NQ rev (1m)-66.67%
EPS NQ rev (3m)44.44%
EPS NY rev (1m)-5.83%
EPS NY rev (3m)-41.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)299.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 111.08
P/S 187.02
P/FCF N/A
P/OCF N/A
P/B 36.25
P/tB 1569.44
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)0.09
Fwd EY0.9%
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS0.05
BVpS0.27
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -132.42%
ROE -250.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.1%
ROA(5y)-55.7%
ROE(3y)-39.94%
ROE(5y)-95.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.5%
Cap/Sales 3.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 0.57
Altman-Z 19.18
F-Score1
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)137.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.59%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y-7.95%
EPS Next 2Y49.03%
EPS Next 3Y39.49%
EPS Next 5YN/A
Revenue 1Y (TTM)-64.52%
Revenue growth 3Y52.8%
Revenue growth 5Y176.68%
Sales Q2Q%-18.11%
Revenue Next Year341.59%
Revenue Next 2Y188.86%
Revenue Next 3Y123.37%
Revenue Next 5YN/A
EBIT growth 1Y-59.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.63%
EBIT Next 3Y56.58%
EBIT Next 5YN/A
FCF growth 1Y-63.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.9%
OCF growth 3YN/A
OCF growth 5YN/A